Chugai Pharmaceutical Co., Ltd. (CUP.F)
- Previous Close
30.25 - Open
29.29 - Bid 29.22 x 64000
- Ask 30.68 x 62400
- Day's Range
29.19 - 29.29 - 52 Week Range
22.00 - 39.80 - Volume
20 - Avg. Volume
83 - Market Cap (intraday)
49.075B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
24.32 - EPS (TTM)
1.20 - Earnings Date --
- Forward Dividend & Yield 0.52 (1.71%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
--
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
www.chugai-pharm.co.jp7,604
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CUP.F
Performance Overview: CUP.F
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CUP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CUP.F
Valuation Measures
Market Cap
50.86B
Enterprise Value
46.37B
Trailing P/E
25.18
Forward P/E
24.04
PEG Ratio (5yr expected)
8.23
Price/Sales (ttm)
7.38
Price/Book (mrq)
5.04
Enterprise Value/Revenue
0.04
Enterprise Value/EBITDA
0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
29.29%
Return on Assets (ttm)
14.44%
Return on Equity (ttm)
21.34%
Revenue (ttm)
1.11T
Net Income Avi to Common (ttm)
325.47B
Diluted EPS (ttm)
1.20
Balance Sheet and Cash Flow
Total Cash (mrq)
738.98B
Total Debt/Equity (mrq)
0.83%
Levered Free Cash Flow (ttm)
317.04B